Funding information SAVOR-TIMI 53 was sponsored by AstraZeneca and Bristol-Myers Squibb. Hypoglycaemia is a well-known risk associated with the use of sulphonylureas and insulin, often limiting achievement of glycaemic goals. Recognizing the precipitants and recurrence patterns of hypoglycaemic events, particularly major events, is therefore clinically important.
Glucose levels reported at the time of the event as well as subsequent actions taken are discussed.
| METHODS
In the SAVOR-TIMI 53 trial, a total of 16 492 patients were randomly assigned to receive saxagliptin or placebo, added to standard of care and were followed for a median period of 2.1 years. 6 Each participant was provided a diary for recording symptoms of hypoglycaemic episodes, any blood glucose values measured at the time of the episode, as well as any value <3.0 mmol/L (54 mg/dL). A hypoglycaemic event could be either an episode with symptoms and confirmed low glucose (glucose levels usually being ≤70 mg/dL, although possibly >70 mg/dL, but approaching that level), or an episode with symptoms which recovered within 30 minutes of carbohydrate ingestion when glucose was not measured. Regardless of the presence of any symptoms, any recorded blood glucose <3.0 mmol/L (54 mg/dL) was to be reported.
A hypoglycaemic event was defined by the investigators as major if it required the assistance of another person to actively administer carbohydrates or glucagon or take other resuscitative actions.
| Statistical analyses
All analyses were conducted on an intention-to-treat basis. The features of each participant's first event are considered. If a participant had multiple hypoglycaemic events on the same day, the more severe event (major over minor) with the most severe symptoms (manifestations of hypoglycaemia, intervention and identifiable precipitant) was selected as the first event.
The characteristics of hypoglycaemic events were compared between the 2 treatments using a chi-squared test. The missing category was excluded from the P-value computation.
Baseline characteristics of participants with single vs multiple events were compared. For continuous variables, the P values were based on ANOVA models with the category of the number of hypoglycaemic adverse events as the factor. For categorical variables, distributions of baseline characteristics were compared by chi-squared test. Participants with 0 events were excluded from the P-value computation.
The statistical software package SAS (version 9.4 SAS Institute, Cary, North Carolina) was used for all analyses, with a 2-sided P value <.05 taken to indicate statistical significance.
The trial was registered under the number: NCT01107886. and 63 mg/dL by 14.2%.
| RESULTS

During
Recurrent vs single events were reported more often in participants with long disease duration and lower glycated haemoglobin (HbA1c) levels. Patients treated with insulin were more likely to report recurrent events, whereas those treated with sulphonylureas at baseline more often reported single events. Major events were more commonly reported in patients reporting >5 events compared with those who reported ≤5
events, yet most patients reporting recurrent events reported only minor and no major events (Table 2) .
| Patients with baseline use of sulphonylureas
Amongst baseline users of sulphonylureas (n = 6586), hypoglycaemic events were reported more often by participants randomized to saxa- Analysis of the features of the first hypoglycaemic event for each participant showed no significant differences between those randomized to saxagliptin and those randomized to placebo (P ≥ .05), except for a higher rate of participants reporting finger-stick glucose values <50 mg/dL with saxagliptin vs placebo (P = .012; Table S1 ).
Ninety-six participants reported major hypoglycaemic events; the majority had been randomized to saxagliptin vs placebo (61/3327, Recurrent vs single events were more prevalent in those with long disease duration, low HbA1c levels and baseline insulin use, similar to the observations in the overall population (Table S2 ).
| DISCUSSION
We hereby report a detailed analysis of hypoglycaemic events and manifestations in a large heterogeneous population with type 2 diabetes who recorded their events for a median duration of 2.1 years.
Hypoglycaemia is common in people with type 2 diabetes who are treated with sulphonylureas or insulin. Retrospective enquiry of the precipitants of the event as well as consideration of means to avoid future events should be encouraged after a hypoglycaemic event, particularly a major event. 5, 8, 9 Approximately half of the participants reported no known identifiable precipitant to any hypoglycaemic event and 40% did not recognize the precipitant to a major event. Open discussion with the patient regarding possible contributors to hypoglycaemia and the means to avert them are an inseparable part of diabetes management; this may increase the number of events in which a precipitating factor could be identified, although inevitably the cause of the event is not always recognized. 5 There is no clear threshold for plasma glucose levels which defines clinical iatrogenic hypoglycaemia in diabetes because the glucose concentration at which signs and symptoms of hypoglycaemia occur is variable between and within individuals. 8 Nevertheless, major events are more likely to occur at lower baseline glucose levels associated with the use of either sulphonylurea or insulin, as observed in the present study.
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An important observation is that in 46.7% of participants reporting major hypoglycaemia, this was the only type of event reported, and in 65.3%, this was the first event reported during the study duration. Although there may have been unrecorded major or minor hypoglycaemic events occurring prior to trial onset and there is the possibility of under-reporting of hypoglycaemic events, this observation indicates that for some participants hypoglycaemia may be initially manifested as a major event. Thus, although minor hypoglycaemic events have been reported to be predictive of major events, major events may also occur independently.
Analysis of the features of the first hypoglycaemic event with saxagliptin vs placebo showed no clinically significant differences.
Focusing on the subgroup of participants with sulphonylurea use at target may therefore be considered appropriate in these patients. [12] [13] [14] Several limitations to the present study should be noted. Our data relied on participant self-reporting of hypoglycaemic events, thus there may have been under-reporting, particularly of minor events. Participants experiencing hypoglycaemia unawareness may have neglected to report minor events. Additionally, the identification of precipitators and consequences of the events was prone to some subjective interpretation. Finally, we can only comment on events that took place during the study, and not on hypoglycaemic events that occurred prior to entry into the trial.
In conclusion, in the SAVOR-TIMI 53 study, regardless of randomization group, many participants presented for the first time with a major hypoglycaemic event, without reporting a precipitating factor or a prior minor hypoglycaemic event. This underscores the need for proper glycaemic target selection, patient education and preference given to prescription of agents known to have low risk of hypoglycaemia, where possible.
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